SF3A2

Across TCGA pan-cancer cohorts, SF3A2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SF3A2 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher SF3A2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SF3A2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

LSCC, HNSC, and GBM are the cancer types where SF3A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.799	0.620	.018	10	view →
HNSC	DFS	Median	III,IV	0.707	0.866	.035	6	view →
GBM	OS	Median	All	0.483	0.283	.014	6	view →
PDAC	OS	Tertile	IV	0.905	0.231	.024	5	view →
LUAD	OS	Quartile	All	0.889	0.572	.030	4	view →
UCEC	DFS	Median	All	1.000	0.936	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SF3A2–LSCC (DFS)

Open the LSCC breakdown →